Osimertinib
About
Therapy type: Targeted therapy
Therapy strategy: EGFR inhibition
Mappings
NCI Thesaurus: Osimertinib (ncit:C116377)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (3) HC (3) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Osimertinib | |
| FDA (3) HC (3) | EGFR p.L858R | Non-Small Cell Lung Cancer | Osimertinib | |
| FDA (1) HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Cisplatin, Osimertinib, Pemetrexed | |
| FDA (1) HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Carboplatin, Osimertinib, Pemetrexed | |
| FDA (1) HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Carboplatin, Osimertinib, Pemetrexed | |
| FDA (1) HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Cisplatin, Osimertinib, Pemetrexed | |
| FDA (1) HC (1) | EGFR p.T790M | Non-Small Cell Lung Cancer | Osimertinib |